Matthew Korenberg
2020
In 2020, Matthew Korenberg earned a total compensation of $3.1M as Executive Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $265,558 |
|---|---|
| Option Awards | $1,206,821 |
| Salary | $482,833 |
| Stock Awards | $1,150,224 |
| Other | $5,700 |
| Total | $3,111,136 |
Korenberg received $1.2M in option awards, accounting for 39% of the total pay in 2020.
Korenberg also received $265.6K in non-equity incentive plan, $482.8K in salary, $1.2M in stock awards and $5.7K in other compensation.
Rankings
In 2020, Matthew Korenberg's compensation ranked 3,735th out of 13,090 executives tracked by ExecPay. In other words, Korenberg earned more than 71.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,735 out of 13,090 | 72nd |
Division Manufacturing | 1,477 out of 5,621 | 74th |
Major group Chemicals And Allied Products | 556 out of 2,254 | 75th |
Industry group Drugs | 482 out of 1,954 | 75th |
Industry Pharmaceutical Preparations | 363 out of 1,459 | 75th |
Source: SEC filing on April 22, 2022.
Korenberg's colleagues
We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2020.